抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展

Programmed death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) are a pair of immune co-inhibitory molecules. Agents targeting the PD-1/PD-L1 pathway reactivated the autologous anti-tumor immune response and yielded strong and prolonged therapeutic effect in various cancer types. However, how to predict whether an individual is sensitive to the anti-PD-1/PD-L1 therapy and how to achieve higher response rates with combined therapies require further investigation. This review summarized the biological mechanism of the PD-1/PD-L1 pathway, the latest results of anti-PD-1/PD-L1 therapy, furthermore probed into potential biomarkers that predict the therapeutic effects and advancements in combined immune therapy.